Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2000

View Archived Issues

Intensive therapy offers persistent benefits in type I diabetes

Large valsartan trial reaches enrollment objectives

Alexion makes significant progress over past six months in various development programs

Vertex enters genomic partnership with Incyte

IL-4 gene therapy studied in malignant glioma

Rebif long-term data confirm dose-related efficacy; Ares-Serono to enhance labeling

CryoLife and Viragen enter cancer therapy collaboration

Ampakine-like compounds and their use described by Lilly

Pharmachemie presents new water-soluble tin compounds with excellent antitumor activity

Guilford to develop novel propofol prodrug discovered by ProQuest

MMP inhibitors from Warner-Lambert particularly active against MMP-2, MMP-3 and MMP-13

International team provides new insight into the mechanics of HIV infection

Pharmaceutically useful neuroprotective agents emerge from R&D at Cambridge NeuroScience

ADIR's new MMP inhibitors particularly useful for cancer, rheumatoid arthritis

U.S./Russian investigators present anesthetics with useful hypometabolic, cardiovascular effects

Estrogen protects against brain damage from ischemic insult in female rats

New vitamin D4 metabolite claimed by Bone Care for vitamin D-deficient states

Schedule-dependent antitumor activity demonstrated for new modified steroidal lactams

Induction therapy with daclizumab in cardiac transplant recipients safe and effective

Actonel to be approved in Europe for Rx of postmenopausal osteoporosis

EpiGenesis and Taisho sign binding letter of intent for EPI-2010

Potent factor XIIIa inhibitor synthesized from naturally occurring cyclopropenones

Collaboration between Novartis and Emisphere extended to include second compound

Progenics announces important discoveries related to HIV fusion inhibitors

Triapine anticancer therapy completes phase I trial

Novantrone moves one step closer to approval for MS

Noven successfully completes phase II study of MethyPatch for treatment of ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...